Skip to main content
Top
Published in: Endocrine 3/2017

Open Access 01-06-2017 | Original Article

The dipeptidyl peptidase-4 (DPP-4) inhibitor teneligliptin functions as antioxidant on human endothelial cells exposed to chronic hyperglycemia and metabolic high-glucose memory

Authors: Gemma Pujadas, Valeria De Nigris, Francesco Prattichizzo, Lucia La Sala, Roberto Testa, Antonio Ceriello

Published in: Endocrine | Issue 3/2017

Login to get access

Abstract

Dipeptidyl peptidase-4 inhibitors are widely used in type 2 diabetes. Endothelium plays a crucial role maintaining vascular integrity and function. Chronic exposure to high glucose drives to endothelial dysfunction generating oxidative stress. Teneligliptin is a novel dipeptidyl peptidase-4 inhibitor with antioxidant properties. This study is aimed to verify a potential protective action of teneligliptin in endothelial cells exposed to high glucose. Human umbilical vein endothelial cells were cultured under normal (5 mmol/L) or high glucose (25 mmol/L) during 21 days, or at high glucose during 14 days followed by 7 days at normal glucose, to reproduce the high-metabolic memory state. During this period, different concentrations of teneligliptin (0.1, 1.0 and 3.0 µmol/L) or sitagliptin (0.5 µmol/L) were added to cells. Ribonucleic acid and protein expression were assessed for antioxidant response, proliferation, apoptosis and endoplasmic reticulum stress markers. Teneligliptin promotes the antioxidant response in human umbilical vein endothelial cells, reducing ROS levels and inducing Nrf2-target genes messenger ribonucleic acid expression. Teneligliptin, but not sitagliptin, reduces the expression of the nicotine amide adenine dinucleotide phosphate oxidase regulatory subunit P22 −phox , however, both blunt the high glucose-induced increase of TXNIP. Teneligliptin improves proliferation rates in human umbilical vein endothelial cells exposed to high glucose, regulating the expression of cell-cycle inhibitors markers (P53, P21 and P27), and reducing proapoptotic genes (BAX and CASP3), while promotes BCL2 expression. Teneligliptin ameliorates high glucose-induced endoplasmic reticulum stress reducing the expression of several markers (BIP, PERK, ATF4, CHOP, IRE1a and ATF6). Teneligliptin has antioxidant properties, ameliorates oxidative stress and apoptotic phenotype and it can overcome the metabolic memory effect, induced by chronic exposure to high glucose in human endothelial cells.
Literature
1.
go back to reference S.C. Smith, Multiple risk factors for cardiovascular disease and diabetes mellitus. Am. J. Med. 120, S3–S11 (2007)CrossRefPubMed S.C. Smith, Multiple risk factors for cardiovascular disease and diabetes mellitus. Am. J. Med. 120, S3–S11 (2007)CrossRefPubMed
2.
go back to reference C.E. Tabit, W.B. Chung, N.M. Hamburg, J.A. Vita, Endothelial dysfunction in diabetes mellitus: molecular mechanisms and clinical implications. Rev. Endocr. Metab. Disord. 11, 61–74 (2010)CrossRefPubMedPubMedCentral C.E. Tabit, W.B. Chung, N.M. Hamburg, J.A. Vita, Endothelial dysfunction in diabetes mellitus: molecular mechanisms and clinical implications. Rev. Endocr. Metab. Disord. 11, 61–74 (2010)CrossRefPubMedPubMedCentral
4.
go back to reference K.K. Griendling, G. FitzGerald, Oxidative stress and cardiovascular injury: Part I: basic mechanisms and in vivo monitoring of ROS. Circulation 108, 1912–1916 (2003)CrossRefPubMed K.K. Griendling, G. FitzGerald, Oxidative stress and cardiovascular injury: Part I: basic mechanisms and in vivo monitoring of ROS. Circulation 108, 1912–1916 (2003)CrossRefPubMed
5.
go back to reference M.A. Ihnat, J.E. Thorpe, A. Ceriello, Hypothesis: the ‘metabolic memory’, the new challenge of diabetes. Diabet. Med 24, 582–586 (2007)CrossRefPubMed M.A. Ihnat, J.E. Thorpe, A. Ceriello, Hypothesis: the ‘metabolic memory’, the new challenge of diabetes. Diabet. Med 24, 582–586 (2007)CrossRefPubMed
6.
go back to reference M.A. Ihnat, J.E. Thorpe, C.D. Kamat, C. Szabó, Reactive oxygen species mediate a cellular ‘memory’ of high glucose stress signalling. Diabetologia 50, 1523–1531 (2007)CrossRefPubMed M.A. Ihnat, J.E. Thorpe, C.D. Kamat, C. Szabó, Reactive oxygen species mediate a cellular ‘memory’ of high glucose stress signalling. Diabetologia 50, 1523–1531 (2007)CrossRefPubMed
7.
go back to reference L.L. Baggio, D.J. Drucker, Biology of incretins: GLP-1 and GIP. Gastroenterology 132, 2131–2157 (2007)CrossRefPubMed L.L. Baggio, D.J. Drucker, Biology of incretins: GLP-1 and GIP. Gastroenterology 132, 2131–2157 (2007)CrossRefPubMed
8.
go back to reference T. Nyström, M.K. Gutniak, Q. Zhang, F. Zhang, J.J. Holst, B. Ahrén, A. Sjöholm, Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am. J. Physiol. Endocrinol. Metab. 287, 1209–1215 (2004)CrossRef T. Nyström, M.K. Gutniak, Q. Zhang, F. Zhang, J.J. Holst, B. Ahrén, A. Sjöholm, Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am. J. Physiol. Endocrinol. Metab. 287, 1209–1215 (2004)CrossRef
9.
go back to reference A. Ceriello, K. Esposito, R. Testa, A.R. Bonfigli, M. Marra, D. Giugliano, The possible protective role of glucagon-like peptide1 on endothelium during the meal and evidence for an ‘endothelial resistance’ to glucagon-like peptide 1 in diabetes. Diabetes Care 34, 697–702 (2011)CrossRefPubMedPubMedCentral A. Ceriello, K. Esposito, R. Testa, A.R. Bonfigli, M. Marra, D. Giugliano, The possible protective role of glucagon-like peptide1 on endothelium during the meal and evidence for an ‘endothelial resistance’ to glucagon-like peptide 1 in diabetes. Diabetes Care 34, 697–702 (2011)CrossRefPubMedPubMedCentral
10.
go back to reference R. Morishita, H. Nakagami, Teneligliptin: expectations for its pleiotropic action. Expert Opin. Pharmacother. 16, 417–426 (2016) R. Morishita, H. Nakagami, Teneligliptin: expectations for its pleiotropic action. Expert Opin. Pharmacother. 16, 417–426 (2016)
11.
go back to reference T. Kadowaki, F. Marubayashi, S. Yokota, M. Katoh, H. Iijima, Safety and efficacy of teneligliptin in Japanese patients with type 2 diabetes mellitus: a pooled analysis of two Phase III clinical studies. Expert Opin. Pharmacother. 16, 971–981 (2015)CrossRefPubMed T. Kadowaki, F. Marubayashi, S. Yokota, M. Katoh, H. Iijima, Safety and efficacy of teneligliptin in Japanese patients with type 2 diabetes mellitus: a pooled analysis of two Phase III clinical studies. Expert Opin. Pharmacother. 16, 971–981 (2015)CrossRefPubMed
12.
go back to reference E.Z. Fisman, A. Tenenbaum, Antidiabetic treatment with gliptins: focus on cardiovascular effects and outcomes. Cardiovasc. Diabetol. 14, 1–13 (2015)CrossRef E.Z. Fisman, A. Tenenbaum, Antidiabetic treatment with gliptins: focus on cardiovascular effects and outcomes. Cardiovasc. Diabetol. 14, 1–13 (2015)CrossRef
13.
go back to reference Y. Ishibashi, T. Matsui, M. Takeuchi, S. Yamagishi, Sitagliptin augments protective effects of GLP-1 against advanced glycation end product receptor axis in endothelial cells. Horm. Metab. Res. 43, 731–734 (2011)CrossRefPubMed Y. Ishibashi, T. Matsui, M. Takeuchi, S. Yamagishi, Sitagliptin augments protective effects of GLP-1 against advanced glycation end product receptor axis in endothelial cells. Horm. Metab. Res. 43, 731–734 (2011)CrossRefPubMed
14.
go back to reference L. Piconi, L. Quagliaro, R. Assaloni, R. Da Ros, A. Maier, G. Zuodar, A. Ceriello, Constant and intermittent high glucose enhances endothelial cell apoptosis through mitochondrial superoxide overproduction. Diabetes. Metab. Res. Rev 22, 198–203 (2006)CrossRefPubMed L. Piconi, L. Quagliaro, R. Assaloni, R. Da Ros, A. Maier, G. Zuodar, A. Ceriello, Constant and intermittent high glucose enhances endothelial cell apoptosis through mitochondrial superoxide overproduction. Diabetes. Metab. Res. Rev 22, 198–203 (2006)CrossRefPubMed
15.
go back to reference T.J. Guzik, S. Mussa, D. Gastaldi, J. Sadowski, C. Ratnatunga, R. Pillai, K.M. Channon, Mechanisms of increased vascular superoxide production in human diabetes mellitus: role of NAD(P)H oxidase and endothelial nitric oxide synthase. Circulation 105, 1656–1662 (2002)CrossRefPubMed T.J. Guzik, S. Mussa, D. Gastaldi, J. Sadowski, C. Ratnatunga, R. Pillai, K.M. Channon, Mechanisms of increased vascular superoxide production in human diabetes mellitus: role of NAD(P)H oxidase and endothelial nitric oxide synthase. Circulation 105, 1656–1662 (2002)CrossRefPubMed
16.
go back to reference C. Gorrini, I.S. Harris, T.W. Mak, Modulation of oxidative stress as an anticancer strategy. Nat. Rev. Drug Discov. 12, 931–947 (2013)CrossRefPubMed C. Gorrini, I.S. Harris, T.W. Mak, Modulation of oxidative stress as an anticancer strategy. Nat. Rev. Drug Discov. 12, 931–947 (2013)CrossRefPubMed
17.
go back to reference L. Perrone, T.S. Devi, K.I. Hosoya, T. Terasaki, L.P. Singh, Thioredoxin interacting protein (TXNIP) induces inflammation through chromatin modification in retinal capillary endothelial cells under diabetic conditions. J. Cell. Physiol. 221, 262–272 (2009)CrossRefPubMed L. Perrone, T.S. Devi, K.I. Hosoya, T. Terasaki, L.P. Singh, Thioredoxin interacting protein (TXNIP) induces inflammation through chromatin modification in retinal capillary endothelial cells under diabetic conditions. J. Cell. Physiol. 221, 262–272 (2009)CrossRefPubMed
18.
go back to reference R.K. Ambasta, P. Kumar, K.K. Griendling, H.W. Schmidt, R. Busse, R.P. Brandes, Direct interaction of the novel Nox proteins with p22phox is required for the formation of a functionally active NADPH oxidase. J. Biol. Chem. 279, 45935–45941 (2004)CrossRefPubMed R.K. Ambasta, P. Kumar, K.K. Griendling, H.W. Schmidt, R. Busse, R.P. Brandes, Direct interaction of the novel Nox proteins with p22phox is required for the formation of a functionally active NADPH oxidase. J. Biol. Chem. 279, 45935–45941 (2004)CrossRefPubMed
19.
go back to reference J. Haendeler, V. Tischler, J. Hoffmann, A.M. Zeiher, S. Dimmeler, Low doses of reactive oxygen species protect endothelial cells from apoptosis by increasing thioredoxin-1 expression. FEBS Lett. 577, 427–433 (2004)CrossRefPubMed J. Haendeler, V. Tischler, J. Hoffmann, A.M. Zeiher, S. Dimmeler, Low doses of reactive oxygen species protect endothelial cells from apoptosis by increasing thioredoxin-1 expression. FEBS Lett. 577, 427–433 (2004)CrossRefPubMed
20.
go back to reference P.F. Vitiello, Y.C.M. Wu, R.J. Staversky, M.A. O’Reilly, p21Cip1 protects against oxidative stress by suppressing ER-dependent activation of mitochondrial death pathways. Free Radic. Biol. Med. 46, 33–41 (2009)CrossRefPubMed P.F. Vitiello, Y.C.M. Wu, R.J. Staversky, M.A. O’Reilly, p21Cip1 protects against oxidative stress by suppressing ER-dependent activation of mitochondrial death pathways. Free Radic. Biol. Med. 46, 33–41 (2009)CrossRefPubMed
21.
go back to reference K. Nakamura, D. Arai, K. Fukuchi, Identification of the region required for the antiapoptotic function of the cyclin kinase inhibitor, p21. Arch. Biochem. Biophys. 431, 47–54 (2004)CrossRefPubMed K. Nakamura, D. Arai, K. Fukuchi, Identification of the region required for the antiapoptotic function of the cyclin kinase inhibitor, p21. Arch. Biochem. Biophys. 431, 47–54 (2004)CrossRefPubMed
22.
go back to reference Y.-C.M. Wu, M.A. O’Reilly, Bcl-X(L) is the primary mediator of p21 protection against hyperoxia-induced cell death. Exp. Lung Res. 37, 82–91 (2011)CrossRefPubMed Y.-C.M. Wu, M.A. O’Reilly, Bcl-X(L) is the primary mediator of p21 protection against hyperoxia-induced cell death. Exp. Lung Res. 37, 82–91 (2011)CrossRefPubMed
23.
go back to reference M. Cnop, F. Foufelle, L.A. Velloso, Endoplasmic reticulum stress, obesity and diabetes. Trends Mol. Med. 18, 59–68 (2012)CrossRefPubMed M. Cnop, F. Foufelle, L.A. Velloso, Endoplasmic reticulum stress, obesity and diabetes. Trends Mol. Med. 18, 59–68 (2012)CrossRefPubMed
24.
go back to reference H. Malhi, R.J. Kaufman, Endoplasmic reticulum stress in liver disease. J. Hepatol. 54, 795–809 (2011)CrossRefPubMed H. Malhi, R.J. Kaufman, Endoplasmic reticulum stress in liver disease. J. Hepatol. 54, 795–809 (2011)CrossRefPubMed
25.
go back to reference J. Li, E. Zhu, L. Shen, J.M. Wan, O. Arnold, T. Peng, Deficiency of Rac1 blocks NADPH oxidase activation, inhibits endoplasmic reticulum stress, and reduces myocardial remodeling in a mouse model of type 1 diabetes. Diabetes 59, 2033–2042 (2010)CrossRefPubMedPubMedCentral J. Li, E. Zhu, L. Shen, J.M. Wan, O. Arnold, T. Peng, Deficiency of Rac1 blocks NADPH oxidase activation, inhibits endoplasmic reticulum stress, and reduces myocardial remodeling in a mouse model of type 1 diabetes. Diabetes 59, 2033–2042 (2010)CrossRefPubMedPubMedCentral
26.
go back to reference L. Ozcan, A.S. Ergin, A. Lu, J. Chung, S. Sarkar, D. Nie, M.G. Myers, U. Ozcan, Endoplasmic reticulum stress plays a central role in development of leptin resistance. Cell Metab. 9, 35–51 (2009)CrossRefPubMed L. Ozcan, A.S. Ergin, A. Lu, J. Chung, S. Sarkar, D. Nie, M.G. Myers, U. Ozcan, Endoplasmic reticulum stress plays a central role in development of leptin resistance. Cell Metab. 9, 35–51 (2009)CrossRefPubMed
27.
go back to reference A. Tsutsumi, H. Motoshima, T. Kondo, S. Kawasaki, T. Matsumura, S. Hanatani, M. Igata, N. Ishii, H. Kinoshita, J. Kawashima, K. Taketa, N. Furukawa, K. Tsuruzoe, T. Nishikawa, E. Araki, Caloric restriction decreases ER stress in liver and adipose tissue in ob/ob mice. Biochem. Biophys. Res. Commun. 404, 339–344 (2011)CrossRefPubMed A. Tsutsumi, H. Motoshima, T. Kondo, S. Kawasaki, T. Matsumura, S. Hanatani, M. Igata, N. Ishii, H. Kinoshita, J. Kawashima, K. Taketa, N. Furukawa, K. Tsuruzoe, T. Nishikawa, E. Araki, Caloric restriction decreases ER stress in liver and adipose tissue in ob/ob mice. Biochem. Biophys. Res. Commun. 404, 339–344 (2011)CrossRefPubMed
29.
go back to reference B. Schisano, A.L. Harte, K. Lois, P. Saravanan, N. Al-Daghri, O. Al-Attas, L.B. Knudsen, P.G. McTernan, A. Ceriello, G. Tripathi, GLP-1 analogue, Liraglutide protects human umbilical vein endothelial cells against high glucose induced endoplasmic reticulum stress. Regul. Pept. 174, 46–52 (2012)CrossRefPubMed B. Schisano, A.L. Harte, K. Lois, P. Saravanan, N. Al-Daghri, O. Al-Attas, L.B. Knudsen, P.G. McTernan, A. Ceriello, G. Tripathi, GLP-1 analogue, Liraglutide protects human umbilical vein endothelial cells against high glucose induced endoplasmic reticulum stress. Regul. Pept. 174, 46–52 (2012)CrossRefPubMed
30.
go back to reference G. Pujadas, V. De Nigris, L. La Sala, R. Testa, S. Genovese, A. Ceriello, The pivotal role of high glucose-induced overexpression of PKCβ in the appearance of glucagon-like peptide-1 resistance in endothelial cells. Endocrine (2015) G. Pujadas, V. De Nigris, L. La Sala, R. Testa, S. Genovese, A. Ceriello, The pivotal role of high glucose-induced overexpression of PKCβ in the appearance of glucagon-like peptide-1 resistance in endothelial cells. Endocrine (2015)
31.
go back to reference U. Ozcan, Q. Cao, E. Yilmaz, A.-H. Lee, N.N. Iwakoshi, E. Ozdelen, G. Tuncman, C. Görgün, L.H. Glimcher, G.S. Hotamisligil, Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 306, 457–461 (2004)CrossRefPubMed U. Ozcan, Q. Cao, E. Yilmaz, A.-H. Lee, N.N. Iwakoshi, E. Ozdelen, G. Tuncman, C. Görgün, L.H. Glimcher, G.S. Hotamisligil, Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 306, 457–461 (2004)CrossRefPubMed
32.
go back to reference E. Ferrannini, R.A. DeFronzo, Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes. Eur. Heart J. 2288–2296 (2015) E. Ferrannini, R.A. DeFronzo, Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes. Eur. Heart J. 2288–2296 (2015)
33.
go back to reference S.P. Marso, G.H. Daniels, K. Brown-Frandsen, P. Kristensen, J.F. Mann, M.A. Nauck, S.E. Nissen, S. Pocock, N.R. Poulter, L.S. Ravn, W.M. Steinberg, M. Stockner, B. Zinman, R.M. Bergenstal, J.B. Buse, LEADER Steering Committee on behalf of the LEADER Trial Investigators: Liraglutide and cardiovascular outcomes in type 2 diabetes.N. Engl. J. Med. (2016). doi: 10.1056/NEJMoa1603827 S.P. Marso, G.H. Daniels, K. Brown-Frandsen, P. Kristensen, J.F. Mann, M.A. Nauck, S.E. Nissen, S. Pocock, N.R. Poulter, L.S. Ravn, W.M. Steinberg, M. Stockner, B. Zinman, R.M. Bergenstal, J.B. Buse, LEADER Steering Committee on behalf of the LEADER Trial Investigators: Liraglutide and cardiovascular outcomes in type 2 diabetes.N. Engl. J. Med. (2016). doi: 10.​1056/​NEJMoa1603827
34.
go back to reference J.B. Green, M.A. Bethel, P.W. Armstrong, J.B. Buse, S.S. Engel, J. Garg, R. Josse, K.D. Kaufman, J. Koglin, S. Korn, J.M. Lachin, D.K. McGuire, M.J. Pencina, E. Standl, P.P. Stein, S. Suryawanshi, F. Van de Werf, E.D. Peterson, R.R. Holman, Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 232–242(2015) J.B. Green, M.A. Bethel, P.W. Armstrong, J.B. Buse, S.S. Engel, J. Garg, R. Josse, K.D. Kaufman, J. Koglin, S. Korn, J.M. Lachin, D.K. McGuire, M.J. Pencina, E. Standl, P.P. Stein, S. Suryawanshi, F. Van de Werf, E.D. Peterson, R.R. Holman, Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 232–242(2015)
35.
go back to reference W.B. White, C.P. Cannon, S.R. Heller, S.E. Nissen, R.M. Bergenstal, G.L. Bakris, T. Perez, P.R. Fleck, C.R. Mehta, S. Kupfer, C. Wilson, W.C. Cushman, F. Zannad, Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N. Engl. J. Med. 1327–1335 (2013) W.B. White, C.P. Cannon, S.R. Heller, S.E. Nissen, R.M. Bergenstal, G.L. Bakris, T. Perez, P.R. Fleck, C.R. Mehta, S. Kupfer, C. Wilson, W.C. Cushman, F. Zannad, Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N. Engl. J. Med. 1327–1335 (2013)
36.
go back to reference B.M. Scirica, D.L. Bhatt, E. Braunwald, P.G. Steg, J. Davidson, B. Hirshberg, P. Ohman, R. Frederich, S.D. Wiviott, E.B. Hoffman, M.A. Cavender, J.A. Udell, N.R. Desai, O. Mosenzon, D.K. McGuire, K.K. Ray, L. Leiter, I. Raz, Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N. Engl. J. Med. 1317–1326 (2013) B.M. Scirica, D.L. Bhatt, E. Braunwald, P.G. Steg, J. Davidson, B. Hirshberg, P. Ohman, R. Frederich, S.D. Wiviott, E.B. Hoffman, M.A. Cavender, J.A. Udell, N.R. Desai, O. Mosenzon, D.K. McGuire, K.K. Ray, L. Leiter, I. Raz, Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N. Engl. J. Med. 1317–1326 (2013)
37.
go back to reference T. Mita, N. Katakami, H. Yoshii, T. Onuma, H. Kaneto, T. Osonoi, T. Shiraiwa, K. Kosugi, Y. Umayahara, T. Yamamoto, H. Yokoyama, N. Kuribayashi, H. Jinnouchi, M. Gosho, I. Shimomura, H. Watada, Alogliptin, a dipeptidyl peptidase 4 inhibitor, prevents the progression of carotid atherosclerosis in patients with type 2 diabetes: the study of preventive effects of alogliptin on diabetic atherosclerosis (SPEAD-A). Diabetes Care. 139–148 (2016) T. Mita, N. Katakami, H. Yoshii, T. Onuma, H. Kaneto, T. Osonoi, T. Shiraiwa, K. Kosugi, Y. Umayahara, T. Yamamoto, H. Yokoyama, N. Kuribayashi, H. Jinnouchi, M. Gosho, I. Shimomura, H. Watada, Alogliptin, a dipeptidyl peptidase 4 inhibitor, prevents the progression of carotid atherosclerosis in patients with type 2 diabetes: the study of preventive effects of alogliptin on diabetic atherosclerosis (SPEAD-A). Diabetes Care. 139–148 (2016)
38.
go back to reference Y. Nakamaru, F. Akahoshi, H. Iijima, N. Hisanaga, T. Kume, Tissue distribution of teneligliptin in rats and comparisons with data reported for other dipeptidyl peptidase-4 inhibitors. Biopharm. Drug Dispos. (2016). doi: 10.1002/bdd.2003 Y. Nakamaru, F. Akahoshi, H. Iijima, N. Hisanaga, T. Kume, Tissue distribution of teneligliptin in rats and comparisons with data reported for other dipeptidyl peptidase-4 inhibitors. Biopharm. Drug Dispos. (2016). doi: 10.​1002/​bdd.​2003
39.
go back to reference S. Kimura, T. Inoguchi, T. Yamasaki, M. Yamato, M. Ide, N. Sonoda, K. Yamada, R. Takayanagi, A novel DPP-4 inhibitor teneligliptin scavenges hydroxyl radicals: in vitro study evaluated by electron spin resonance spectroscopy and in vivo study using DPP-4 deficient rats. Metabolism 65, 138–145 (2015)CrossRefPubMed S. Kimura, T. Inoguchi, T. Yamasaki, M. Yamato, M. Ide, N. Sonoda, K. Yamada, R. Takayanagi, A novel DPP-4 inhibitor teneligliptin scavenges hydroxyl radicals: in vitro study evaluated by electron spin resonance spectroscopy and in vivo study using DPP-4 deficient rats. Metabolism 65, 138–145 (2015)CrossRefPubMed
40.
go back to reference H. Nakagami, Z. Pang, T. Shimosato, T. Moritani, H. Kurinami, H. Koriyama, A. Tenma, M. Shimamura, R. Morishita, The dipeptidyl peptidase-4 inhibitor teneligliptin improved endothelial dysfunction and insulin resistance in the SHR/NDmcr-cp rat model of metabolic syndrome. Hypertens. Res. 37, 629–35 (2014)CrossRefPubMed H. Nakagami, Z. Pang, T. Shimosato, T. Moritani, H. Kurinami, H. Koriyama, A. Tenma, M. Shimamura, R. Morishita, The dipeptidyl peptidase-4 inhibitor teneligliptin improved endothelial dysfunction and insulin resistance in the SHR/NDmcr-cp rat model of metabolic syndrome. Hypertens. Res. 37, 629–35 (2014)CrossRefPubMed
41.
go back to reference M. Sagara, K. Suzuki, C. Aoki, S. Tanaka, I. Taguchi, T. Inoue, Y. Aso, Impact of teneligliptin on oxidative stress and endothelial function in type 2 diabetes patients with chronic kidney disease: a case-control study. Cardiovasc. Diabetol. (2016). doi: 10.1002/bdd.2003 M. Sagara, K. Suzuki, C. Aoki, S. Tanaka, I. Taguchi, T. Inoue, Y. Aso, Impact of teneligliptin on oxidative stress and endothelial function in type 2 diabetes patients with chronic kidney disease: a case-control study. Cardiovasc. Diabetol. (2016). doi: 10.​1002/​bdd.​2003
42.
go back to reference J. Matsubara, S. Sugiyama, K. Sugamura, T. Nakamura, Y. Fujiwara, E. Akiyama, H. Kurokawa, T. Nozaki, K. Ohba, M. Konishi, H. Maeda, Y. Izumiya, K. Kaikita, H. Sumida, H. Jinnouchi, K. Matsui, S. Kim-Mitsuyama, M. Takeya, H. Ogawa, A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein edeficient mice. J. Am. Coll. Cardiol. 59, 265–276 (2012)CrossRefPubMed J. Matsubara, S. Sugiyama, K. Sugamura, T. Nakamura, Y. Fujiwara, E. Akiyama, H. Kurokawa, T. Nozaki, K. Ohba, M. Konishi, H. Maeda, Y. Izumiya, K. Kaikita, H. Sumida, H. Jinnouchi, K. Matsui, S. Kim-Mitsuyama, M. Takeya, H. Ogawa, A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein edeficient mice. J. Am. Coll. Cardiol. 59, 265–276 (2012)CrossRefPubMed
43.
go back to reference N. Ervinna, T. Mita, E. Yasunari, K. Azuma, R. Tanaka, S. Fujimura, D. Sukmawati, T. Nomiyama, A. Kanazawa, R. Kawamori, Y. Fujitani, H. Watada, Anagliptin, a DPP-4 inhibitor, suppresses proliferation of vascular smooth muscles and monocyte inflammatory reaction and attenuates atherosclerosis in male apo e-deficient mice. Endocrinology 154, 1260–1270 (2013)CrossRefPubMed N. Ervinna, T. Mita, E. Yasunari, K. Azuma, R. Tanaka, S. Fujimura, D. Sukmawati, T. Nomiyama, A. Kanazawa, R. Kawamori, Y. Fujitani, H. Watada, Anagliptin, a DPP-4 inhibitor, suppresses proliferation of vascular smooth muscles and monocyte inflammatory reaction and attenuates atherosclerosis in male apo e-deficient mice. Endocrinology 154, 1260–1270 (2013)CrossRefPubMed
44.
go back to reference S.G. Fonseca, M. Burcin, J. Gromada, F. Urano, Endoplasmic reticulum stress in β-cells and development of diabetes. Curr. Opin. Pharmacol. 9, 763–770 (2009)CrossRefPubMedPubMedCentral S.G. Fonseca, M. Burcin, J. Gromada, F. Urano, Endoplasmic reticulum stress in β-cells and development of diabetes. Curr. Opin. Pharmacol. 9, 763–770 (2009)CrossRefPubMedPubMedCentral
Metadata
Title
The dipeptidyl peptidase-4 (DPP-4) inhibitor teneligliptin functions as antioxidant on human endothelial cells exposed to chronic hyperglycemia and metabolic high-glucose memory
Authors
Gemma Pujadas
Valeria De Nigris
Francesco Prattichizzo
Lucia La Sala
Roberto Testa
Antonio Ceriello
Publication date
01-06-2017
Publisher
Springer US
Published in
Endocrine / Issue 3/2017
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-016-1052-0

Other articles of this Issue 3/2017

Endocrine 3/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.